Deep-Dive Due Diligence AI Generated Report on Windtree Therapeutics, Inc. Common Stock (WINT)
Welcome to ScanScor. What you're reading is not just a stock summary -- it's a real-time, AI-generated due diligence session crafted from live news, financial data, insider trading activity, SEC filings, and live market momentum.
These reports are generated using OpenAI's GPT-based analysis engine, guided by tightly structured prompts and expert-level data ingestion. Every insight below was assembled to help you understand the forces behind today's market movers.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
WINT_OUT_1 [2025-03-24 07:30:57 -0400] 2151 Bytes | 568 tokens | Cum: 568 tkns (7.10% of 8k)
==========================================================================
We're scouting for winners today. Its 7:30:56 AM on Mon Mar 24, 2025 -0400 and I'm looking at Windtree Therapeutics (WINT) up to 1.99 from 1.48
Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.
Here's the first list of news for Windtree Therapeutics:
C1 - Mar-20-25 08:27AM - Windtree shares rise as it announces agreement to become sourcing partner for Evofem
C2 - Mar-20-25 08:27AM 08:00AM - Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
C3 - Mar-04-25 08:00AM - Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure
C4 - Feb-27-25 08:00AM - Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India
C5 - Feb-18-25 08:00AM - Windtree Therapeutics, Inc. Announces Reverse Stock Split
C6 - Feb-12-25 08:00AM - Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference
C7 - Jan-15-25 08:00AM - Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline
C8 - Jan-13-25 08:00AM - Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Windtree Therapeutics (WINT)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".
WINT_IN_2 [2025-03-24 07:30:57 -0400] 2 Bytes | 2 tokens | Cum: 570 tkns (7.12% of 8k)
==========================================================================
C2
WINT_OUT_3 [2025-03-24 07:31:02 -0400] 1047 Bytes | 290 tokens | Cum: 860 tkns (10.75% of 8k)
==========================================================================
Showing C2 (chunk 1 of 10): C2:
**Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product**
Date: Mar-20-25 08:27AM 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/20/3046178/0/en/Windtree-Announces-License-and-Supply-Agreement-to-Become-Sourcing-Partner-for-a-Small-Biotech-with-an-FDA-Approved-Product.html
March 20, 2025 08:00 ET| Source:Windtree TherapeuticsWindtree Therapeutics
WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce that it has entered into a License and Supply Agreement to become the sourcing partner for Evofem Biosciences, Inc
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
WINT_IN_4 [2025-03-24 07:31:02 -0400] 334 Bytes | 65 tokens | Cum: 925 tkns (11.56% of 8k)
==========================================================================
Windtree Therapeutics, a biotechnology company, has announced a License and Supply Agreement with Evofem Biosciences, making Windtree a sourcing partner for the biotech company. This move aligns with Windtree's goal of becoming a revenue-generating biotech firm and advancing innovative therapies for critical conditions and diseases.
WINT_OUT_5 [2025-03-24 07:31:04 -0400] 987 Bytes | 302 tokens | Cum: 1227 tkns (15.34% of 8k)
==========================================================================
We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.
A1 - 2025-03-24T09:18:47Z - Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - AZEK Co (NYS...
A2 - 2025-03-21T21:05:50Z - 12 Health Care Stocks Moving In Friday's After-Market Session - Aspira Womens Health (NASDAQ:AWH), C...
A3 - 2025-03-21T20:02:35Z - Top Small Cap Stocks To Watch Today - March 20th...
A4 - 2025-03-21T17:05:38Z - 12 Health Care Stocks Moving In Friday's Intraday Session - GlucoTrack (NASDAQ:GCTK), CervoMed (NASD...
A5 - 2025-03-20T17:06:07Z - 12 Health Care Stocks Moving In Thursday's Intraday Session - Akebia Therapeutics (NASDAQ:AKBA), Ada...
Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.
WINT_IN_6 [2025-03-24 07:31:04 -0400] 2 Bytes | 2 tokens | Cum: 1229 tkns (15.36% of 8k)
==========================================================================
A1
WINT_OUT_7 [2025-03-24 07:31:05 -0400] 1038 Bytes | 299 tokens | Cum: 1528 tkns (19.10% of 8k)
==========================================================================
Showing A1 (chunk 1 of 5): A1:
**Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - AZEK Co (NYSE:AZEK), Bit Origin (NASDAQ:BTOG)**Date: 2025-03-24Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/03/44453127/why-azek-shares-are-trading-higher-by-around-18-here-are-20-stocks-moving-premarketShares of The AZEK Company Inc. AZEK rose sharply in today's pre-market trading after James Hardie Industries plc JHX announced plans to acquire the company for $8.75 billion.
The AZEK Company shares jumped 18.2% to $48.94 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
Gainers Windtree Therapeutics, Inc. WINT rose 54.7% to $2.29 in pre-market trading after tumbling 32% on Friday. Windtree recently entered a license and supply agreement to become a sourcing partner for Evofem Biosciences for
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
WINT_IN_8 [2025-03-24 07:31:05 -0400] 3 Bytes | 2 tokens | Cum: 1530 tkns (19.12% of 8k)
==========================================================================
NEX
WINT_OUT_9 [2025-03-24 07:31:07 -0400] 998 Bytes | 294 tokens | Cum: 1824 tkns (22.80% of 8k)
==========================================================================
This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!
B1 - 2025-01-13T13:00:00Z - Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
B2 - 2024-12-09T13:00:00Z - Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
B3 - 2024-07-10T22:16:16Z - Eagle Point Income reports NAV per share and quarterly earnings By Investing.com - Investing.com
B4 - 2024-04-18T12:00:00Z - Windtree Therapeutics Announces Reverse Stock Split
B5 - 2024-04-08T20:48:00Z - Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
B6 - 2024-02-01T13:00:00Z - Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.
WINT_IN_10 [2025-03-24 07:31:07 -0400] 2 Bytes | 2 tokens | Cum: 1826 tkns (22.82% of 8k)
==========================================================================
B3
WINT_OUT_11 [2025-03-24 07:31:11 -0400] 651 Bytes | 159 tokens | Cum: 1985 tkns (24.81% of 8k)
==========================================================================
Showing B3 (chunk 1 of 1): B3:
**Eagle Point Income reports NAV per share and quarterly earnings By Investing.com - Investing.com**Date: Unknown DateSource: Unknown SourceURL: https://www.investing.com/news/company-news/windtree-therapeutics-secures-200000-in-private-notes-93CH-3514739Windtree Therapeutics, a biotechnology firm, has secured $200,000 in private notes, including senior secured and unsecured promissory notes. The company has also seen recent developments such as a reverse stock split and securing new financing options.
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
WINT_IN_12 [2025-03-24 07:31:11 -0400] 311 Bytes | 62 tokens | Cum: 2047 tkns (25.59% of 8k)
==========================================================================
This news piece reports that Windtree Therapeutics, a biotechnology firm, has secured $200,000 in private notes. These notes include both senior secured and unsecured promissory notes. In addition to this, the company has experienced recent developments, such as a reverse stock split and new financing options.
WINT_OUT_13 [2025-03-24 07:31:13 -0400] 1151 Bytes | 302 tokens | Cum: 2349 tkns (29.36% of 8k)
==========================================================================
This is our list of SEC filings.
If empty, the search returned no recent filings.
S1 - 2025-02-18 8-K Item 7.01. Regulation FD Disclosure.
On February 18, 2025, the Company issued a press release announcing the Reverse Stock Split. The press release is furnished as Exhibit 99.1 and incorporated by reference herein.
The information in this Item 7.01, including Exhibit 99.1 atta...
S2 - 2025-02-18 8-K Item 7.01. Regulation FD Disclosure.
On February 18, 2025, the Company issued a press release announcing the Reverse Stock Split. The press release is furnished as Exhibit 99.1 and incorporated by reference herein.
The information in this Item 7.01, including Exhibit 99.1 atta...
S3 - 2025-02-18 8-K Item 7.01. Regulation FD Disclosure.
On February 18, 2025, the Company issued a press release announcing the Reverse Stock Split. The press release is furnished as Exhibit 99.1 and incorporated by reference herein.
The information in this Item 7.01, including Exhibit 99.1 atta...
Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.
WINT_IN_14 [2025-03-24 07:31:13 -0400] 2 Bytes | 2 tokens | Cum: 2351 tkns (29.39% of 8k)
==========================================================================
S1
WINT_OUT_15 [2025-03-24 07:31:14 -0400] 1038 Bytes | 237 tokens | Cum: 2588 tkns (32.35% of 8k)
==========================================================================
Showing S1 (chunk 1 of 3): S1:
Item 7.01. Regulation FD Disclosure.
On February 18, 2025, the Company issued a press release announcing the Reverse Stock Split. The press release is furnished as Exhibit 99.1 and incorporated by reference herein.
The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended (the Securities Act), whether made before or after the date hereof, except as expressly set forth by specific reference in such filing. The furnishing of this information will not be deemed an admission as to the materiality of any information contained therein.
Forward-Looking St
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
WINT_IN_16 [2025-03-24 07:31:14 -0400] 3 Bytes | 2 tokens | Cum: 2590 tkns (32.38% of 8k)
==========================================================================
NEX
WINT_OUT_17 [2025-03-24 07:31:29 -0400] 4251 Bytes | 1205 tokens | Cum: 3795 tkns (47.44% of 8k)
==========================================================================
This is our set of metrics.
Please analyze the numbers.
+-------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+
| Volume: 3,676,177 | SMA50: -75.05% | Market Cap: 1.04M | Option/Short: No / No | Sales past 5Y: -25.00% | Sales Surprise: - |
+-------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 2.44M | SMA200: -98.80% | Shs Outstand: 0.75M | Short Float: 11.07% | Employees: 15 | EPS Surprise: - |
+-------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 1.44 | Perf Week: -27.80% | Shs Float: 0.75M | Short Ratio: 0.03 | Debt/Eq: 1.68 | P/E: - |
+-------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 25.28 | Perf Month: -69.17% | Inst Own: 0.84% | Short Interest: 0.08M | Sales Y/Y TTM: - | Earnings: Nov 27 AMC |
+-------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.71 | Perf Quarter: -92.21% | Insider Own: 0.13% | Beta: 0.86 | ROE: -138.34% | |
+-------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+
| SMA20: -37.72% | Index: - | Insider Trans: - | Sales Q/Q: - | ROI: -146.00% | |
+-------------------+-----------------------+---------------------+-----------------------+------------------------+----------------------+
The next section covers any insider trading.
If this section may be blank due to no recent filings.
No transactions recorded.
[Company Financial Summary]
[Company Details]
Name: Windtree Therapeutics, Inc. Common Stock
Market Cap: 1109024.68
Shares Outstanding: 749341
Sector: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -9708000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A
[Price Metrics - Last 30 Days]
Latest Close: 1.48
Average Volume: 6873204.2
30-Day High: 3.77
30-Day Low: 1.48
[Detailed Financials: Q3 2024]
- Total Assets: $30,448,000.0
- Total Liabilities: $23,897,000.0
- Total Equity: $4,409,000.0
- Current Assets: $3,928,000.0
- Current Liabilities: $14,426,000.0
[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -4.23
[Cash Flow Statement: Q3 2024]
- Net Cash Flow: N/A
[Detailed Financials: Q1 2024]
- Total Assets: $30,103,000.0
- Total Liabilities: $14,682,000.0
- Total Equity: $15,421,000.0
- Current Assets: $3,339,000.0
- Current Liabilities: $4,985,000.0
[Income Statement: Q1 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 21.98
[Cash Flow Statement: Q1 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====
You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.
Now, complete this report with the following:
1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]
1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE
WINT_IN_18 [2025-03-24 07:31:29 -0400] 1070 Bytes | 239 tokens | Cum: 4034 tkns (50.42% of 8k)
==========================================================================
1) Brief Summary: Windtree Therapeutics, Inc. is currently underperforming with a negative sales growth over the past 5 years, and a considerable decline in performance over the week, month, and quarter. The company has a high debt-to-equity ratio of 1.68 which indicates financial risk. The company also doesn't generate any revenue, which is a significant concern. Despite an average volume of 2.44M, the company has a small market cap of just 1.04M and a relatively small number of outstanding shares (0.75M). The company's insider ownership is minimal, which could be a potential red flag.
2) MARKET_SCORE[15]: Given the company's poor performance indicators and lack of revenue, there is only a 15% likelihood of an upward move in the near term.
3) PRICE_TARGET[$1.48]: Considering the company's underperformance and financial instability, it is difficult to foresee any significant increase in the share price. Thus, the price target is set at the current price level.
4) AI_RPT_HEADLINE: "Windtree Therapeutics Struggling with Poor Performance and No Revenue"
WINT_OUT_19 [2025-03-24 07:31:31 -0400] 676 Bytes | 167 tokens | Cum: 4201 tkns (52.51% of 8k)
==========================================================================
Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)
WINT_IN_20 [2025-03-24 07:31:31 -0400] 94 Bytes | 28 tokens | Cum: 4229 tkns (52.86% of 8k)
==========================================================================
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
WINT_IN_21 [2025-03-24 07:31:32 -0400] 126 Bytes | 29 tokens | Cum: 4258 tkns (53.23% of 8k)
==========================================================================
====================================
[2025-03-24 04:31:32] # Analysis Completed
Elapsed Time: 36.27 seconds